. 2022 Jun 21;23:164. doi: 10.1186/s12931-022-02082-x

Table 3.

Summary clinical findings for meta-analysis and descriptive review cohorts

Meta-analysis (N = 14 studies)
52 ± 7	184/77 (not delineated in two studies (N = 35))	SSc = 120 RA = 98 ASS = 22 SS = 12 SLE = 7 IIM = 8 Unclassifiable = 4	Fibrotic = 290* OP = 3 Nodular or GGO = 4	Non-response to prior therapy = 260 Firstline = 3 Randomized = 33

Meta-analysis (N = 14 studies)

Age (mean age ± SD)

Sex (F/M)

Disease type

ILD (fibrotic vs non-fibrotic)

Rationale for initiating RTX

52 ± 7

184/77 (not delineated in two studies (N = 35))

SSc = 120

RA = 98

ASS = 22

SS = 12

SLE = 7

IIM = 8

Unclassifiable = 4

Fibrotic = 290*

OP = 3

Nodular or GGO = 4

Non-response to prior therapy = 260

Firstline = 3

Randomized = 33

Descriptive analysis (N = 6 studies)
56 ± 3	41/34 (not delineated in one study (N = 31))	SSc = 3 RA = 39 ASS = 52 IIM = 3 MCTD = 2 Unclassifiable = 1	Fibrotic = 95* OP = 2 LIP = 1 Unclassified = 1	Non-response to prior therapy = 62 Firstline = 7 (Not delineated in 2 studies (N = 38))

Descriptive analysis (N = 6 studies)

Age (mean age)

Sex (F/M)

Disease type

ILD (fibrotic vs non-fibrotic)

Rationale for initiating RTX

56 ± 3

41/34 (not delineated in one study (N = 31))

SSc = 3

RA = 39

ASS = 52

IIM = 3

MCTD = 2

Unclassifiable = 1

Fibrotic = 95*

OP = 2

LIP = 1

Unclassified = 1

Non-response to prior therapy = 62

Firstline = 7

(Not delineated in 2 studies (N = 38))

ASS antisynthetase syndrome, F female, GGO ground glass opacities, IIM idiopathic inflammatory myopathy, ILD interstitial lung disease LIP lymphocytic interstitial pneumonia, M male, MCTD mixed connective tissue disease, OP organizing pneumonia, RTX rituximab, RA rheumatoid arthritis, SLE systemic lupus erythematosus, SSc scleroderma or systemic sclerosis, SD standard deviation

^*Inclusive of mixed fibrotic and GGO infiltrates, usual interstitial pneumonia, nonspecific interstitial pneumonia (NSIP), and NSIP with organizing pneumonia